Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of SecuritiesGlobeNewsWire • 04/23/26
ALT Stock and the 2026 MASH Race: Dual Agonists vs. New MechanismsZacks Investment Research • 03/26/26
Altimmune, Inc. (ALT) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptSeeking Alpha • 03/12/26
Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business UpdatesGlobeNewsWire • 03/05/26
Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026GlobeNewsWire • 02/26/26
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common StockGlobeNewsWire • 01/29/26
Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common StockGlobeNewsWire • 01/28/26
Investor Bets $100k On David v Goliath Matchup With Altimmune and Eli Lilly24/7 Wall Street • 01/23/26
ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASHZacks Investment Research • 01/06/26
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASHGlobeNewsWire • 01/05/26
Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH TranscriptSeeking Alpha • 12/19/25
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH TrialGlobeNewsWire • 12/19/25
Does Altimmune (ALT) Have the Potential to Rally 229.28% as Wall Street Analysts Expect?Zacks Investment Research • 12/11/25